Jump to content

1cP-AL-LAD

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Boghog (talk | contribs) at 12:37, 29 June 2024 (consistent citation formatting). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

1cP-AL-LAD
Identifiers
  • (6aR,9R)-4-(cyclopropanecarbonyl)-N,N-diethyl-7-prop-2-enyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
UNII
Chemical and physical data
FormulaC26H31N3O2
Molar mass417.553 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@@H]1C=C2[C@@H](Cc3cn(C(=O)C4CC4)c4cccc2c34)N(C1)CC=C
  • InChI=1S/C26H31N3O2/c1-4-12-28-15-19(25(30)27(5-2)6-3)13-21-20-8-7-9-22-24(20)18(14-23(21)28)16-29(22)26(31)17-10-11-17/h4,7-9,13,16-17,19,23H,1,5-6,10-12,14-15H2,2-3H3/t19-,23-/m1/s1
  • Key:VSABTUDYQCMWKE-AUSIDOKSSA-N

1cP-AL-LAD is an analog of lysergic acid diethylamide (LSD) which has psychedelic effects and is thought to act as a prodrug for AL-LAD. It has been sold as a designer drug, first identified in France in June 2021.[1]

See also

[edit]

References

[edit]
  1. ^ Morais J, Evans-Brown M, Gallegos A, Christie R, Jorge R, Planchuelo G, et al. (2022-09-01). "New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System". Toxicologie Analytique et Clinique. 30th meeting of SFTA- 59th meeting of TIAFT - September 2022. 34 (3, Supplement): S29–S30. doi:10.1016/j.toxac.2022.06.022. ISSN 2352-0078.